Nano Dentica AB
2026-04-16 10:13 by Sara Drougge
Problem | Secondary caries is a public health challenge, only in Sweden 500.000 dental fillings are replaced due to secondary caries every year, a trend that has not changed in the past 10 years. Moreover, bacterial-driven problems, like peri-implantitis, do not have a clear prevention and treatment protocols.
Solution | Fluorapatite, a known crystalline mineral, has the ability to halt the growth of these bacteria without significant problems to the patients. We are the first company in the world to take the production of fluorapatite to an industrial scale.
Potential | Fluorapatite can be incorporated into different materials to prevent this diseases, and perhaps even to treat them, in that sense we deliver materials that do more for the patient. Grounded in clinical reality do deal with real clinical challenges.
Bioelectrix
2025-11-10 16:16 by Sara Drougge
Bioelectrix Sweden AB is a MedTech startup pioneering bioelectronic wound care, focused on accelerating healing in hard-to-heal wounds through safe, controlled direct current therapy delivered in a simple dressing format, complemented by continuous sensing in future versions. Their mission is to move wound care from passive management to active repair, improving outcomes for patients and easing the burden on clinicians and healthcare systems.
The lead product concept uses metal free electrodes to reproduce the body’s electric fields that guide cell migration, aiming for faster re-epithelialisation, with a clear roadmap to integrate impedance, pH, and temperature monitoring for data driven care.
LayerLogic
2024-05-10 09:54 by Admin
LayerLogic’s advanced biosensor technology rivals the sensitivity of PCR tests but offers the distinct advantages of full portability and immediate digital results. Capable of detecting and quantifying any bacteria, virus, fungi, or molecule, our biosensors ensure rapid and precise monitoring in various products and environments, such as fish, cheese, and food production facilities. This enables real-time quality control, minimizes contamination risks, and upholds the highest food safety standards. With LayerLogic, customers benefit from a secure and reliable production process, reduced costs across the supply chain, and decreased food waste. Ultimately, our technology not only prevents serious illnesses but also boosts revenue. It all boils down to one critical factor: TIME.
Galaxy Biosolutions
2024-04-23 14:39 by Admin
ANYO Labs
2023-03-14 13:38 by Admin
ANYO Labs is an early drug discovery company with a novel patent pending artificial intelligence scoring method unlike any other on the market. With the help of molecular biology scientists and professor, this unique method allows for extreme data and energy efficient ways of finding drug compounds for further testing in the lab and clinical trials.
The market potential is very large and is targeted towards chemisty research facilities as well as small and big pharmacauticul institutions.
We have incorporated in december 2022, secured funding from Chalmers Ventures, have validated our technolgy through benchmarks, case studies, customer interviews, a pilot project, and are in discussion with a research facility as well as a global pharmaceutical company about further projects and further collaboration. We have also recently filed for a patent. We are now looking into synthesising our own compounds and compare them to our predicted parameters to validate our technology even further.
Lanterna
2022-04-05 10:38 by Admin
Beat Vascular Health
2022-02-03 10:39 by Admin
Overadmission of patients with suspected Acute Coronary Syndrome (ACS) is a big problem in healthcare and can be as much as 80% of the admitted patients, vastly increasing healthcare expenditure and workload.
Beat Vascular Health is developing a decision support tool that has the potential to be a game-changer for diagnosing suspected ACS patients. The uniqueness of the tool lies in the way it processes input data from different sensor types. This, combined with machine learning, results in a tool that can produce a more precise answer on whether or not a patient has ACS. With our system, we aim to greatly reduce the overadmission of suspected ACS patients, resulting in less healthcare expenditure and workload, as well as reducing the number of patients having to go through unnecessary diagnostic testing.
Navari
2021-09-02 10:40 by Admin
Navari is solving a navigation-issue that surgeons encounter during laparoscopic liver surgery when removing liver tumours. Today, the most beneficial way for the patient is to have a tumour removed minimally-invasive, i.e. through laparoscopic surgery. However, surgeons face a big challenge when operating through a limited point of view, trying to orient themselves via the laparoscopic camera. By using existing gadgets and screens in the surgery room, Navari develops a software that provides the surgeon with a live-streamed augmented reality image on top of the already existing image provided by the laparoscopic camera. This helps the surgeons to orient themselves during the surgery, enabling them to locate and remove the tumour in the safest way possible.
Nyctea Technologies
2021-04-30 10:04 by Admin
The purpose of Nyctea Technologies is to increase the efficiency in the production of biological pharmaceuticals.
Antibodies, gene vectors and vaccines are effective treatments against a growing number of diseases. However, they are expensive to produce and slow to develop restricting global access to the best available pharmaceuticals. The main contributor to the cost of production, is the separation of the pharmaceutical compound from other biomolecules made by the cells during harvest.
Nyctea Technologies develops an electrode filter that can capture and release biopharmaceuticals by electronic signals. This enables a new and more efficient method of separation between biological molecules, which can increase the speed and control in development and production of life saving treatments.
The long-term ambition is to create the next generation digitalized and automated systems for every step in the biomedical industry, from production and analysis to diagnostics and drug-delivery.
Vitroprobe
2020-02-05 13:48 by Admin
Vitroprobe Analytics performs biomolecular analysis at the atomic scale to help design the pharmaceutical drugs of tomorrow. The development of new effective pharmaceutical drugs to fight disease is a slow and expensive process. Successful drug design relies on a profound understanding of the interactions between drug candidates and their target molecules in the body. The company has developed a unique platform to analyze target molecular structure in3D with simultaneous identification of individual constituent atoms. With the novel patented technique drug targets can be examined one atom at a time, thereby enabling fine-tuning of new pharmaceutical substances. The technology is the result of an interdisciplinary research program at Chalmers University of Technology.